Skip to main content

Anna Duarri Piqué

Institutions of which they are part

Postdoctoral researcher
Ophtalmology
Vall Hebron Institut de Recerca

Research lines

CeO2 Nanoparticles-assisted stem-based cell therapy: an innovative nanopharmaceutical approach to treat retinal degenerative diseases

Chronic inflammation is now regarded as a major pathogenic pathway common in many different pathologies. This is the case of Age-related Macular Degeneration (AMD), a disease currently inevitable, orphan of treatment that represents a major cause of blindness in people over 50, and affects millions of people worldwide. The progression of AMD is associated to an increase of oxidative stress and inflammatory response in the eye leading to retinal cell death. Current studies suggest that antioxidant therapies for chronic inflammation treatment are a feasible objective to stop disease progression and represent a promising strategy to improve the therapeutic benefits of regenerative medicine to restore vision (since inflammation impedes proper regeneration). CeO2nanoparticles have a unique electronic structure that when reduced to the nanoscale, oxygen defects appear at their surface, behaving as sites for free radical scavenging. Thus, the main objective of CELLUX is to develop a novel pharmaceutical-based CeO2 nanoparticles eye drops to treat AMD that in combination with stem cell-based therapeutic strategies, will not only stop degeneration but restore vision. The accomplishment of the objectives will represent a significant advance in the current concept of nanomedicine to treat degenerative diseases.

IP: Anna Duarri Piqué

Projects

CeO2 Nanoparticles-assisted stem cell therapy: an innovative nanopharmaceutical approach to treat retinal degenerative diseases.

IP: Anna Duarri Piqué
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: CLIENT
Reference: ISCIII/EURONANOMED/2019/DUARRI
Duration: 10/10/2019 - 10/10/2019

Terapia basada en células madre asistida con nanopartículas de Ce02: un enfoque nanofarmacéutico innovador para tratar enfermedades degenerativas de la retina.

IP: Anna Duarri Piqué
Collaborators: José García Arumí, Victor Franco Puntes, Muriel Freixanet Gustà, Helena Isla Magrané, Joana Ramis Garcia
Funding agency: Instituto de Salud Carlos III
Funding: 174845
Reference: AC19/00080
Duration: 01/01/2020 - 31/12/2022

Related news

Els estudis avançaran en els camps de les malalties digestives, el VIH, la fatiga crònica, les patologies cardíaques, l’hepatitis, la diabetis i l’oftalmologia.

Dr. José García Arumi and Dr. Anna Duarri from the Ophthalmology research group at Vall Hebron Recerca lead the project. 

Related professionals

Carlos Salvador Lacambra

Carlos Salvador Lacambra

Read more
Mercedes Pallero Castillo

Mercedes Pallero Castillo

Pneumology
Read more
Monica Rodriguez Carballeira

Monica Rodriguez Carballeira

Administration and Management
Read more
Laura  Escot Garcia

Laura Escot Garcia

Read more

Subscriu-te als nostres butlletíns i forma part de la vida del Campus

El Vall d’Hebron Barcelona Hospital Campus és un parc sanitari de referència mundial on assistència, recerca, docència i innovació es donen la mà.